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Vascular endothelial growth factor (VEGF) is a potent angiogenic factor in solid tumors. However, its role in angiogenesis
in pituitary adenoma is controversial. Angiogenesis in solid tumors including pituitary adenoma is commonly evaluated by
microvascular density (MVD). Here, we evaluated MVD and the role of VEGF in vascular architecture in 51 pituitary adenomas
(24 nonfunctioning, 13 prolactin-secreting, 10 growth hormone-secreting, 3 adrenocorticotropic hormone-secreting, and 1 thyroid-
stimulating hormone-secreting). Paraffin sections were stained with CD34 and VEGF. MVD and vascular architecture parameters
(vessel area, diameter, perimeter, and roundness) were evaluated in CD34-stained sections. Immunohistochemistry showed 27/51
tumors (53%) were VEGF-positive. There were no significant differences in MVD, any vascular parameter, or adenoma volume
between VEGF-positive and VEGF-negative tumors. VEGF mRNA expression was significantly higher in VEGF-positive tumors.
There were no significant correlations between VEGF mRNA expression and MVD or vascular parameters. However, vessel
diameter and perimeter were significantly larger in prolactin-secreting than nonfunctioning and growth hormone-secreting
macroadenomas. The difference in vessel diameter was observed among both VEGF-positive and all adenomas (micro- and
macroadenoma). Thus, VEGF may have limited roles in the development of vascular architecture and tumor angiogenesis in
pituitary adenomas, but the differences in vessel architecture by histotype (i.e., larger vessel diameter and perimeter in prolactin-
secreting adenomas) suggest the hormonal regulation of vessel architecture rather than angiogenesis
1. Introduction
Angiogenesis, a fundamental process in tumor growth and
development, is less prominent in adenomas than normal
pituitary tissue [1–3]. The behavior of angiogenesis as a
function of hormonal secretion and other characteristics
of pituitary tumors remain controversial [4–8]. Vascular
endothelial growth factor (VEGF) is a potent angiogenic
factor expressed in many solid tumors [9]. It is considered an
important biomarker in pituitary neoplasms [10]. VEGF was
discovered in the conditioned medium of pituitary follicular
cells in 1989 [11] and is still focused there as of 2012 [12].
Moreover, VEGF may be an important humoral factor for
both normal and tumorous pituitary tissues.
The degree of angiogenesis in solid tumors including
pituitary adenomas is commonly evaluated by microvascular
density (MVD), inwhich the number of vessels in a given area
is counted. However, angiogenesis possesses many aspects
of neovascularization, such as vessel number, branching pat-
tern, diameter, and shape. Among pituitary hormones, pro-
lactin (PRL) and adrenocorticotropic hormone (ACTH) are
reported to be related to vascular development and endothe-
lial cell function [13–15]. Therefore, these hormone-secreting
adenomas may have different vasculature and angiogenic
characteristics compared to other types of adenomas.
Therefore, this study determined the roles of VEGF in
angiogenesis and vascular architecture in pituitary adenomas.
In addition, the differences in vascular architecture param-
eters other than MVD were determined between different
histotypes of pituitary adenomas.
2. Materials and Methods
2.1. Pituitary Adenoma Samples. A total of 51 pituitary
adenomas (24 nonfunctioning, 13 PRL-secreting, 10 growth
Hindawi Publishing Corporation
International Journal of Endocrinology
Volume 2014, Article ID 989574, 12 pages
http://dx.doi.org/10.1155/2014/989574
2 International Journal of Endocrinology
(a) (b)
(c) (d)
Figure 1: Determination of microvascular density and vascular architecture (a, b) and VEGF immunohistochemistry (c, d). CD34-stained
fields (1.0mm2) (a) are input into the image analyzer, and each vessel contour is manually traced in order to measure vessel density (number),
vessel area (%), vessel diameter (𝜇m), vessel perimeter (𝜇m), and vessel roundness (0-1) (b). The area of the black box in (a) is magnified to
(b). VEGF immunohistochemistry: positive tumor with clear cytoplasmic staining (c) and negative tumor (d). Original magnification (a):
200x, (c), (d): 400x. Bar 100𝜇m.
hormone- (GH-) secreting, 3 ACTH-secreting, and 1 thyroid-
stimulating hormone- (TSH-) secreting) obtained during
surgery were fixed in formalin, embedded in paraffin,
and sectioned at 5𝜇M. The adenoma volume was mea-
sured by magnetic resonance imaging according to the
3-dimensional diameter (AP: maximum diameter of the
anterior-to-posterior direction in a sagittal section; LR: max-
imum diameter of the left-to-right direction in a coronal
section; up and down: maximum diameter of the up-to-
down direction in a coronal or sagittal section). The cystic
component of the adenoma was measured separately and not
included in the calculation. Macroadenomas (i.e., >10mm
in diameter in one dimension) were observed in 24 of 24
nonfunctioning, 10 of 13 PRL-secreting, 8 of 10 GH-secreting,
2 of 3 ACTH-secreting, and 0 of 1 TSH-secreting adenomas.
For functioning adenomas, preoperative serum hormone
levels (i.e., GH, PRL, and ACTH) were determined.
2.2. CD34 and VEGF Immunohistochemistry and Measure-
ment of Vascular Architecture. Paraffin sections were stained
with monoclonal anti-CD34 antibody (1 : 100, M7165; Dako)
and polyclonal anti-VEGF antibody (1 : 100, A20; Santa Cruz)
by the streptavidin-biotin-peroxidase method (Dako LSAB2
System) as described previously [16]. The same concentra-
tions of chromatographically purified mouse IgG and rabbit
IgG (Dako) were used as negative controls. CD34-stained
sections were evaluated for MVD, and vascular architecture
parameters including vessel area, diameter, perimeter, and
roundness were analyzed by using an image analyzer system
(WinROOF, Mitani Corporation, Japan); WinROOF is an
integrated software system for image processing, measure-
ment, and data processing to support all image analysis-
related operations [17, 18]. The defined area for the measure-
ment of these parameterswas 1.0mm2. CD34-stained fields of
1.0mm2 (Figure 1(a)) were input into the image analyzer, and
each vessel contour was manually traced in order to measure
vessel density (number), vessel area (%), vessel diameter
(𝜇m), vessel perimeter (𝜇m), and vessel roundness (0-1;
1 = completely round) (Figure 1(b)). Three different fields in
each case were measured, and the median values were used
for analysis. VEGF immunohistochemistry was defined as
positive if more than 10% of adenoma cells were positive.
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2.3. VEGF mRNA Expression by RT-PCR. Among the 51
pituitary adenomas, frozen tissues of 19 adenomas (12
nonfunctioning, 4 PRL-secreting, 2 GH-secreting, and 1
ACTH-secreting) were available. Total RNA was extracted,
and VEGF mRNA expression was measured by RT-PCR
as described previously [19]. Briefly, 1 𝜇g total RNA was
reverse-transcribed by MuLV reverse transcriptase in the
presence of random hexamers followed by the indicated
cycles of PCR (95∘C for 1min, 55∘C for 1min, and 72∘C for
1min) in the presence of 2 𝜇M VEGF-specific primers (28
cycles) or 𝛽-actin-specific primers (16 cycles) as a control.
The VEGF primers included the reverse primer (5󸀠-CCT-
GGTGAGAGATCTGGTTC-3󸀠) spanning bases 861–842 and
the forward primer (5󸀠-TCGGGCCTCCGAAACCATGA-
3󸀠) spanning bases 141–160. The 𝛽-actin primers included
the reverse primer (5󸀠-GGAGTTGAAGGTAGTTTCGTG-
3󸀠) spanning bases 2429–2409 and the forward primer (5󸀠-
CGGGAAATCGTGCGTGACAT-3󸀠) spanning bases 2107–
2126.The VEGF primers were chosen because they amplified
exons 3–8, enabling us to distinguish VEGF splicing variants.
PCR products of 516 and 648 bp corresponded with VEGF
121
and VEGF
165
, respectively. RT-PCR products were quantified
by densitometry.
2.4. Statistical Analysis. Vascular density, tumor volume, the
densitometric values of VEGF and 𝛽-actin, and adenoma
architecture parameters (i.e., area, diameter, perimeter, and
roundness) are expressed as mean ± SD. The one-way
ANOVA with post hoc Tukey’s comparisons was used for
multiple groups, while the 𝑡-test was used for comparisons
of 2 groups. Pearson’s correlation coefficients (𝑟) were also
calculated. All 𝑃 values are two-sided, and the level of
significance was set at 𝑃 < 0.05.
3. Results
3.1. VEGF Expression and Pituitary Adenoma. Immunohis-
tochemistry showed 27/51 tumors (53%) were positive for
VEGF (Figures 1(c) and 1(d)). There were no significant
differences between the VEGF-positive and VEGF-negative
groups with respect to MVD, any vascular architecture
parameter, or adenoma volume (Table 1). In 19 tumors, VEGF
mRNA and protein expressions were measured simultane-
ously (Figure 2(a)).TheVEGF
165
/actin ratio was significantly
higher in VEGF-positive tumors (0.81 ± 0.91) than negative
tumors (0.46 ± 0.23) (𝑃 = 0.045, Figure 2(b)). Likewise,
the VEGF
121
/actin ratio was significantly higher in VEGF-
positive tumors (0.74 ± 0.37) than negative tumors (0.39 ±
0.24) (𝑃 = 0.019, Figure 2(c)). There was no significant
correlation between VEGF
165
or VEGF
121
mRNA expression
and MVD or any vascular architecture parameter (Table 2,
Figures 2(d), 2(e), 2(f), and 2(g)). Thus, these results indicate
VEGF has only small roles in the vascular architecture and
angiogenesis of pituitary adenomas.
3.2. Vascular Architecture in Different Histotypes of Pitu-
itary Adenomas. The vascular architecture parameters in
different histotypes of adenomas are shown in Table 3 and
Table 1
VEGF
pos
VEGF-
negative Statistics
mean SD mean SD
All cases n 27 n 24
Density/1.0mm2 57.2 30.6 46.0 27.80 ns
Area % 7.17 5.54 5.24 2.89 ns
Diameter 𝜇m 12.3 0.6 12.5 0.56 ns
Perimeter 𝜇m 58.9 18.4 59.4 13.40 ns
Roundness 0.55 0.06 0.55 0.08 ns
Tumor volume
mm3 28035.7 97661.7 4342 4500.9 ns
NF n 11 n 13
Density/1.0mm2 63.8 11.1 50.6 8.50 ns
Area % 7.13 5.37 5.49 3.00 ns
Diameter 𝜇m 11.9 2.65 12.2 2.30 ns
Perimeter 𝜇m 56.4 17.4 55.1 11.40 ns
Roundness 0.56 0.03 0.58 0.08 ns
Tumor volume
mm3 13519.1 16887.9 6648.1 4654.6 ns
PRL n 7 n 6
Density/1.0mm2 50.3 9.8 42.6 11.10 ns
Area % 9.19 5.18 5.73 3.12 ns
Diameter 𝜇m 14.9 2.98 13.3 3.10 ns
Perimeter 𝜇m 72 15.7 62.1 15.20 ns
Roundness 0.515 0.054 0.545 0.05 ns
Tumor volume
mm3 8245.8 189920.0 2817.9 4305.9 ns
GH n 8 n 2
Density/1.0mm2 51 27.1 59.4 15.10 ns
Area % 5.59 6.56 5.98 3.43 ns
Diameter 𝜇m 10.8 2.8 10.8 2.10 ns
Perimeter 𝜇m 52.1 18.9 56.8 12.50 ns
Roundness 0.557 0.070 0.473 0.033 ns
Tumor volume
mm3 3842.1 5570.5 500.0 282.8 ns
ACTH n 0 n 3
Density/1.0mm2 nd 24.2 13.30 nd
Area % nd 2.72 0.76 nd
Diameter 𝜇m nd 13.5 4.70 nd
Perimeter 𝜇m nd 66.5 20.70 nd
Roundness nd 0.481 0.057 nd
Tumor volume
mm3 nd 2264.8 1976.50 nd
TSH n 1 n 0
Density/1.0mm2 51 27.1 nd nd
Area % 5.59 6.56 nd nd
Diameter 𝜇m 10.8 2.8 nd nd
Perimeter 𝜇m 52.1 18.9 nd nd
Roundness 0.557 0.070 nd nd
Tumor volume
mm3 346.5 nd nd nd
Figure 3. Vessel diameter was significantly larger in PRL-
secreting adenomas than GH-secreting adenomas (Figure 4).
Meanwhile, vessel density and area tended to be lower in
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Figure 2: Determination of VEGF mRNA expression and immunohistochemistry. (a) VEGF mRNA expression and corresponding VEGF
immunohistochemistry results (positive and negative) and vessel density (number/0.13mm2,𝐻 ≥ 40, 𝐿 < 40). (b)TheVEGF
165
/𝛽-actin ratio
was significantly higher in VEGF-positive group than the VEGF-negative group (𝑃 < 0.05). (c) The VEGF
121
/𝛽-actin ratio was significantly
higher in the VEGF-positive group than the VEGF-negative group (𝑃 < 0.05). (d)The correlation between VEGF
165
/𝛽-actin ratio and vessel
density was not significant (𝑟 = 0.22). (e) Correlation between VEGF
121
/𝛽-actin ratio and vessel density is not significant (𝑟 = 0.169). (f)
Correlation between VEGF
165
/𝛽-actin ratio and vessel diameter is not significant (𝑟 = 0.143). (g) Correlation between VEGF
121
/𝛽-actin ratio
and vessel density is not significant (𝑟 = 0.175).
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Figure 3: Representative vascular architecture (CD34 stain) of nonfunctioning (a), prolactin-secreting (b), GH-secreting (c), and ACTH-
secreting (d) macroadenomas. Vessel diameter is larger in prolactin- and ACTH-secreting adenomas than nonfunctioning and GH-secreting
adenomas. Vessel density and area are lower in ACTH-secreting adenoma than nonfunctioning and PRL-secreting adenomas. Original
magnification: 200x. Bar 100 𝜇m.
Table 2
mRNA expression Parameters 𝑟 Statistics
VEGF165/actin
Density 0.220 ns
Area 0.301 ns
Diameter 0.143 ns
Perimeter 0.260 ns
Roundness −0.026 ns
Tumor volume 0.110 ns
VEGF121/actin
Density 0.169 ns
Area 0.292 ns
Diameter 0.175 ns
Perimeter 0.218 ns
Roundness 0.056 ns
Tumor volume 0.270 ns
ACTH-secreting adenomas than nonfunctioning adenomas,
although the differences were not significant. Because VEGF
may influence vascular architecture, VEGF-positive adeno-
mas alone (𝑛 = 27) were analyzed. Again, vessel diameter
was significantly larger in PRL-secreting adenomas thanGH-
secreting adenomas. Because adenoma volumemay influence
vascular architecture, macroadenomas alone (𝑛 = 44)
were analyzed. PRL-secreting adenomas had significantly
larger perimeter and vessel diameter than nonfunctioning
and GH-secreting adenomas (Figure 5). In summary, PRL-
secreting adenomas, especially macroadenomas, have larger
diameters and perimeters than nonfunctioning and GH-
secreting adenomas.
In PRL-secreting adenomas, serum PRL level was
strongly correlated with adenoma volume (𝑟 = 0.9679,
𝑃 < 0.001, Figure 6(a)). However, adenoma volume was not
correlated with other vessel architecture parameters (density:
𝑟 = 0.2008, 𝑃 = 0.5313; area: 𝑟 = 0.3315, 𝑃 = 0.2925;
diameter: 𝑟 = 0.162, 𝑃 = 0.6146; perimeter: 𝑟 = 0.138, 𝑃 =
0.6685; roundness: 𝑟 = −0.168, 𝑃 = 0.6014). Furthermore,
in GH-secreting adenomas, serum GH level was strongly
correlated with adenoma volume (𝑟 = 0.9412, 𝑃 < 0.001,
Figure 6(b)).
4. Discussion
Vascular architecture parameters differed among adenoma
histotypes. Inmacroadenomas, PRL-secreting adenomas had
larger vessel diameter and perimeter than nonfunctioning
and GH-secreting adenomas. In all adenomas (including
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Table 3: Morphometric analysis of vascular architecture between adenoma function.
NF PRL GH ACTH TSH
mean SD mean SD mean SD mean SD mean
All cases n 24 n 13 n 10 n 3 n 1
Density/1.0mm2 56.6 33.5 46.8 25.7 52.7 24.6 24.2 13.3 83
Area % 6.24 4.24 7.59 4.55 5.66 5.90 2.72 0.76 6.27
Diameter 𝜇m 12.1 2.4 14.1∗ 3.0 10.8 2.6 13.5 4.7 9.58 ∗𝑃 < 0.05 to GH
Perimeter 𝜇m 55.7 14.2 67.5 15.7 53.0 17.3 66.5 20.7 47.5
Roundness 0.57 0.06 0.529 0.053 0.54 0.072 0.481 0.057 0.471
VEGF-positive case n 11 n 7 n 8 n 0 n 1
Density/1.0mm2 63.8 36.7 50.3 25.9 51.0 27.1 nd 83
Area % 7.13 5.37 9.19 5.18 5.59 6.56 nd 6.27
Diameter 𝜇m 11.9 2.7 14.9∗ 3.0 10.8 2.8 nd 9.58 ∗𝑃 < 0.05 to GH
Perimeter 𝜇m 56.4 17.4 72.0 15.7 52.1 18.9 nd 47.5
Roundness 0.564 0.032 0.515 0.0543 0.557 0.0699 nd 0.471
Macroadenoma case n 24 n 10 n 8 n 2 n 0
Density/1.0mm2 56.6 33.3 44.3 24.1 49.2 24.9 16.7 23.3 nd
Area % 6.2 4.2 8.4 4.6 5.7 6.60 3.1 0.32 nd
Diameter 𝜇m 12.1 2.4 15.2∗∗ 2.4 11.1 2.8 16.2 0.2 nd ∗∗𝑃 < 0.01 to NF, GH
Perimeter 𝜇m 55.7 14.2 72.7∗ 12.9 53.3 19.4 78.3 4.7 nd ∗𝑃 < 0.05 to NF, GH
Roundness 0.571 0.064 0.527 0.060 0.558 0.069 0.503 0.060 nd
macro- and microadenomas) and VEGF-positive adeno-
mas, vessel diameter in PRL-secreting adenomas was larger
than that in GH-secreting adenomas. In addition, VEGF
expression did not reveal any differences in MVD, vascular
architecture, or tumor volume among adenoma histotypes.
Thus, VEGF expression in pituitary adenoma has little effect
on angiogenesis, vascular architecture, or histotype.
4.1. Role of VEGF in Pituitary Adenomas. VEGF is a potent
angiogenic factor for solid tumors. The global standard for
the measurement of tumor and physiological angiogenesis
is immunohistochemical counting of vessels per defined
hotspot area, that is,MVD, owing to its simplicity [20].There-
fore, angiogenesis of pituitary adenomas has been reported
in many recent studies evaluating VEGF protein expression
(measured by immunohistochemistry and western blot anal-
ysis), VEGF mRNA expression, and MVD. Nevertheless, the
role of VEGF in angiogenesis in pituitary adenoma remains
inconclusive. VEGF is reported to be a potent angiogenic
factor in pituitary adenomas [4]. On the contrary, VEGF is
found equally in normal tissue and adenomas and among
tumors of different histotype [3]. Pituitary tumor cells are
capable of producing VEGF, whichmay be involved in tumor
angiogenesis [21]. Furthermore, VEGF mRNA and protein
are expressed in all pituitary adenomas [22]. Thus, these
findings suggest VEGFmay not be a potent angiogenic factor
in pituitary adenomas.
One of the reasons for these controversial results is the
limitation of immunohistochemistry, which is semiquanti-
tative. Also, MVD is only one aspect of neovascularization.
Therefore, as an alternative, the present study evaluated
angiogenesis by immunohistochemistry as well as mRNA
expression to evaluate VEGF expression and vascular archi-
tecture parameters, and MVD.
A recent study demonstrates that VEGF mRNA expres-
sion differs among histological subtypes. The extension on
magnetic resonance imaging indicates VEGF expression is
related to suprasellar extension, being expressed more on
tumors with extrasellar growth than intrasellar growth [23].
However, no relationship between VEGF expression and
MVD was found in the present study. Hence, VEGF may be
related to tumor growth (e.g., inhibition of apoptosis) but not
tumor angiogenesis.
In the present study, high VEGF protein and mRNA
expression did not reflect MVD, vascular architecture, tumor
volume, or any particular histotype, suggesting VEGF plays
little role in pituitary adenoma angiogenesis and growth.
Stromal cell-derived factor-1 (SDF-1) is reported to be related
toMVD in pituitary adenoma as a CD34-positive endothelial
progenitor cell homing factor [24]. Hence, studies investigat-
ing the regulation of this novel angiogenic factor and VEGF
in the angiogenesis of pituitary adenomas are warranted.
4.2. Vascular Architecture. MVD is one of the most
widely used estimators of tumor microvascularity in two-
dimensional histological sections [5, 25]. However, MVD has
several substantial limitations mainly owing to the complex
biology of tumor microvasculature [26] and the irregular
geometry that microvascular systems assume in real space
[27]. Until now, the finding that MVD in the normal anterior
pituitary was significantly higher than that in tumors was
generally accepted [3, 7]. However, the differences in MVD
among adenoma histotypes are highly discordant in the
literature. Adenomas with higher MVD are thyrotroph
International Journal of Endocrinology 7
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Figure 4: Differences in the vascular architecture of all types of pituitary adenomas. Vessel diameter is significantly larger in prolactin-
secreting adenomas than GH-secreting adenomas. Vessel density, area, and roundness are lower tendency in ACTH-secreting adenoma than
nonfunctioning adenomas. ∗𝑃 < 0.05.
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Figure 5: Differences of vascular architecture in macroadenoma. Vessel diameter and perimeter are significantly larger in prolactin-secreting
adenomas than nonfunctioning and GH-secreting adenomas. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01.
cell adenomas, while those with lower MVD are PRL cell
adenomas [6]. Micro- and macroadenomas that secrete
GH or ACTH have comparable vascular densities, whereas
macroprolactinomas are significantly more vascular than
microprolactinomas [8].
Several methods for quantitatively analyzing pituitary
adenoma microvasculature besides MVD have been applied.
Fractal analysis is emerging as a potential effective model for
this aim [1]. In addition, the combination of different types
of immunostaining techniques such as CD105 (Endoglin)
International Journal of Endocrinology 9
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Figure 6: Correlation between adenoma volume and hormone value. (a) Prolactin-secreting adenomas. (b) GH-secreting adenomas.
[28, 29] and Endocan [30] for the detection of microvessels
in pituitary adenomas by using fractal analysis is an objective
computer-aided technique for quantifying and describing
the morphological aspects of microvessels that has potential
implications in future clinical and surgical applications [2].
Geometrically, human vascularity is a complex three-
dimensional system; its sizes, shapes, and connecting patterns
are highly variable in two-dimensional histological sections.
This geometrical complexity is the main cause of discordant
results when assessing microvascularity in surgical tissue
specimens [1].
In 2003, Vidal et al. suggested using microvascular
structural entropy as a new index for the simultaneous
measurement of the size of vessels and their arrangements
in two-dimensional sections of pituitary tumors [31]. They
found that microvascular structural entropy is significantly
higher in pituitary adenomas thanPRL-secreting carcinomas.
In 2007, Di leva et al. first estimated the global complexity
of the two-dimensional microvasculature of normal pituitary
glands and pituitary adenomas by quantifying their box
counting fractal dimension [1].They found that themicrovas-
culature of normal pituitary specimens is significantly more
geometrically complex than that of pituitary adenomas. On
the basis of the principles of fractal geometry, this indicates
normal pituitary tissue is more vascularized than pituitary
adenomas and that the microvasculature of normal pituitary
glands is more complex than that of pituitary adenomas.
These studies collectively highlight the importance of using
geometrical vascular architectural elements other thanMVD
to evaluate the complex form of tumor vascularity.
However, these geometrical analyses require complex
calculations. MVD is only one functional aspect of a tumor
microvascular bed; other aspects such as morphology (i.e.,
tortuosity, branching pattern, and microvessel diameter),
maturation, and endothelial wall permeability represent
equally important attributes. Among these vessel architecture
parameters, we chose simple parameters—vessel diameter,
perimeter, and roundness—in addition to MVD. The results
demonstrate the importance of vessel diameter and perimeter
as biomarkers of different histotypes; PRL-secreting adeno-
mas had larger vessel diameter and perimeter than nonfunc-
tioning and GH-secreting adenomas.
4.3. Significance of Larger Vessel Diameter and Perimeter
in PRL-Secreting Adenomas. With regard to PRL-secreting
adenomas, vascularity evaluated by MVD is reported to
be related to pretreatment hormone production, invasive-
ness, and surgical cure with lower vascularity [8]. However,
whether PRL also influences endothelial cells and whether
there are functional consequences of PRL-induced signal-
ing from the perspective of angiogenesis remains elusive.
PRL directly stimulates endothelial cell migration and tube
formation both in vitro and in vivo in chorioallantoic
membrane [32]. In the present study, serum PRL level
was strongly correlated with adenoma volume as described
previously. However, serum PRL level did not reflect specific
vascular architecture parameters. Hyperprolactinemia with
PRL-secreting adenomas may have some effect on tumor
vasculature.
Blood vessels are emerging as important PRL targets,
contributing to PRL’s hormonal functions. PRL promotes
angiogenesis and is proteolytically cleaved into vasoinhibins,
a family of peptides (including 16 kDa PRL) with potent
antiangiogenic and blood vessel regression effects [33, 34];
16 kDa PRL impairs functional tumor neovascularization by
inhibiting vessel maturation and for the first time demon-
strated that an endogenous antiangiogenic agent disturbs
notch signaling [35]. Recent results suggest tissue enzymes
play an important role in the production of this form of
PRL in several tissues including the retina, myocardium, and
mammary glands. The cleavage leading to the production
of 16 kDa PRL may occur extracellularly in the interstitial
medium and therefore in the vicinity of blood capillaries [36].
Like PRL-secreting adenomas, circulating levels of PRL
are elevated in diabetes; accordingly, they are higher in
diabetes patients without retinopathy than in those with
proliferative diabetic retinopathy, which is an angiogenic
10 International Journal of Endocrinology
disease. Circulating PRL influences the progression of dia-
betic retinopathy after its intraocular conversion to vasoin-
hibins. Therefore, inducing hyperprolactinemia may repre-
sent a novel treatment strategy against diabetic retinopathy
[37].
The synthesis of antiangiogenic factors by tumor cells
has been demonstrated. Actively growing primary tumors
can secrete antiangiogenic factors into the circulation as is
the case for angiostatin and endostatin, which can maintain
tumors in a dormant state [38, 39]. It remains unknown if
PRL-secreting adenomas can produce antiangiogenic factors
such as 16 kDa PRL. PRL and/or its inhibitor may directly
influence adenoma vasculature. In gliomas treated with beva-
cizumab, an anti-VEGF antibody, tumor vasculature becomes
dilated and thin, which suggests normalization, compared
to that in nontreated tissue in experimental animals [40]
and humans [41, 42]. In contrast, in human corneal neo-
vascularization, topical bevacizumab decreases corneal vessel
diameter [43]. Meanwhile, the effect of somatostatin analog
treatment on vessel diameter in PRL-secreting adenomas
would be interesting to investigate in the future.
4.4. Significance of Vessel Architecture in ACTH-Secreting Ade-
nomas. There are few studies concerning ACTH-secreting
adenomas, vascularity, and/or vascular architecture. Among
46 adenomas (18 nonfunctioning, 12 ACTH-secreting, 12
GH-secreting, and 4 PRL-secreting), there was no difference
among histotypes with respect to MVD [3]. In another
report of 112 (30GH-secreting, 25 PRL-secreting, 15 ACTH-
secreting, and 42 nonfunctioning tumors) and 13 normal
anterior pituitary gland specimens, ACTH-secreting adeno-
mas were, like microprolactinomas, hadmuch lower vascular
density than the normal pituitary tissue and other secreting
and nonsecreting tumor types [7]. Micro- and macroadeno-
mas that secrete ACTH have comparable vascular densities
[8]. In the present study, ACTH-secreting adenomas tended
to have larger vessel diameter and perimeter and lower
density than nonfunctioning and GH-secreting adenomas.
The direct action of ACTH on vessels has not been
reported. However, the direct actions of cortisol on endothe-
lial cells and vascular permeability have been demonstrated.
Interestingly, glucocorticoids directly interact with gluco-
corticoid receptors on vascular endothelial cells to inhibit
tube-like formation. This action is due to alterations in cell
morphology rather than the inhibition of endothelial cell
viability, migration, or proliferation and may be mediated in
part by the induction of thrombospondin-1 [44]. Therefore,
ACTH-secreting adenomas may alter vascular architecture.
5. Conclusion
VEGF expression plays little role in angiogenesis in pituitary
adenomas. Taken together the fact that pituitary adenomas
are hypovascular compared to the normal pituitary gland, in
biological terms, we can speculate that pituitary adenomas
may progress via a nonangiogenic and VEGF-independent
pathway. The differences in vessel architecture in different
histotypes, particularly larger vessel diameter and perimeter
in PRL-secreting adenomas than nonfunctioning and GH-
secreting adenomas, suggest the hormonal regulation of
vessel architecture other than angiogenesis.
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